Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (41-50 of 283) with videos related to

Pageof 29
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2003
Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility studyWilliam Blum, Hanna Khoury, H-S Lin, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 2003
Recent advances in allogeneic hematopoietic stem-cell transplantationSteven M Devine, Douglas R Adkins, Hanna Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2019
EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible MechanismsScott R Goldsmith, Mark A Fiala, Julie O'Neal, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2018
Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of TreatmentMary-Kate Malecek, Mark Fiala, Mark Schroeder, et al.
Leukemia & Lymphoma|February 21, 2015
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myelomaRavi Vij, Michael Wang, Sundar Jagannath, et al.
Cancer Genetics|September 4, 2012
Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myelomaVishwanathan Hucthagowder, Rekha Meyer, Chelsea Mullins, et al.
JCO Oncology Practice|March 6, 2024
Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple MyelomaMark A Fiala, Matthew R Leblanc, Kathryn W Coccia, et al.
British Journal of Haematology|January 6, 2016
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myelomaBarbara Muz, Pilar de la Puente, Feda Azab, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphomaTanya M Wildes, Kristan M Augustin, Diane Sempek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2016
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell TransplantationAmanda F Cashen, Theresa Fletcher, Connie Ceriotti, et al.
Pageof 29

Showing results (41-50 of 283) with videos related to

Sort By:
Pageof 29
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2003
Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility studyWilliam Blum, Hanna Khoury, H-S Lin, et al.
The Journal of Laboratory and Clinical Medicine|January 9, 2003
Recent advances in allogeneic hematopoietic stem-cell transplantationSteven M Devine, Douglas R Adkins, Hanna Khoury, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2019
EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible MechanismsScott R Goldsmith, Mark A Fiala, Julie O'Neal, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2018
Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of TreatmentMary-Kate Malecek, Mark Fiala, Mark Schroeder, et al.
Leukemia & Lymphoma|February 21, 2015
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myelomaRavi Vij, Michael Wang, Sundar Jagannath, et al.
Cancer Genetics|September 4, 2012
Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myelomaVishwanathan Hucthagowder, Rekha Meyer, Chelsea Mullins, et al.
JCO Oncology Practice|March 6, 2024
Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple MyelomaMark A Fiala, Matthew R Leblanc, Kathryn W Coccia, et al.
British Journal of Haematology|January 6, 2016
A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myelomaBarbara Muz, Pilar de la Puente, Feda Azab, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2008
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphomaTanya M Wildes, Kristan M Augustin, Diane Sempek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2016
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell TransplantationAmanda F Cashen, Theresa Fletcher, Connie Ceriotti, et al.
Pageof 29